<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847573</url>
  </required_header>
  <id_info>
    <org_study_id>HALO-DMD-01</org_study_id>
    <secondary_id>HALO</secondary_id>
    <nct_id>NCT01847573</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Phase 1b Open Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-100 in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akashi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akashi Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to test the safety and tolerability of different,
      increasing doses of an experimental medication called HT-100 in boys and young men with
      Duchenne muscular dystrophy (DMD). The study medication, HT-100, is a medicine that may help
      promote healthy muscle regeneration, diminish inflammation and the resulting damage to
      muscle, and decrease the scar tissue that forms in the muscles of children with DMD. In this
      study, pharmacokinetic sampling, or measurements of the amount of HT-100 in the bloodstream
      will also be taken.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Dosing stopped
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 21, 2017</completion_date>
  <primary_completion_date type="Actual">April 21, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of administering single and multiple ascending doses of HT-100 in DMD boys</measure>
    <time_frame>1 week</time_frame>
    <description>Safety profile by review of adverse events (AEs), physical examination findings, clinical laboratory test results, and other diagnostic testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic plasma profile of halofuginone after single and multiple dose administration of HT-100 in DMD boys</measure>
    <time_frame>1 week</time_frame>
    <description>Halofuginone plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of administering multiple ascending doses of HT-100 in DMD boys over 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Safety profile by review of AEs, physical examination findings, clinical laboratory test results, and other diagnostic testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early pharmacodynamic signals of HT-100 after 4 weeks of continuous dosing in DMD boys</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pharmacodynamic measures relevant to DMD pathology:
Pulmonary function
Motor function
Muscle composition
Biochemical and imaging markers</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: HT-100 tablet, Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration: Dose 1
Multiple dose administration: Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: HT-100 tablet, Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration: Dose 2
Multiple dose administration: Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: HT-100 tablet, Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration: Dose 3
Multiple dose administration: Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4a: HT-100 tablet, Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration: Dose 4
Multiple dose administration: Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4b: HT-100 tablet, Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Multiple dose administration: Dose 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: HT-100 tablet, Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>* Multiple dose administration: Dose 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HT-100</intervention_name>
    <description>May be administered in either fed or fasted state</description>
    <arm_group_label>Cohort 1: HT-100 tablet, Dose 1</arm_group_label>
    <arm_group_label>Cohort 2: HT-100 tablet, Dose 2</arm_group_label>
    <arm_group_label>Cohort 3: HT-100 tablet, Dose 3</arm_group_label>
    <arm_group_label>Cohort 4a: HT-100 tablet, Dose 4</arm_group_label>
    <arm_group_label>Cohort 4b: HT-100 tablet, Dose 5</arm_group_label>
    <arm_group_label>Cohort 5: HT-100 tablet, Dose 6</arm_group_label>
    <other_name>halofuginone hydrobromide delayed-release tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Ambulatory or non-ambulatory

          -  Diagnosis of DMD with confirmation of minimal to no dystrophin

          -  Corticosteroid naive or on therapy for at least 12 months (stable dose and regimen)

        Main Exclusion Criteria:

          -  Recent, substantial change in use of cardiac medications or medications affecting
             muscle function

          -  Inability to undergo magnetic resonance imaging (MRI)

          -  Significantly compromised cardio-respiratory function

          -  Prior treatment with another investigational product in past 6 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana M Escolar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Akashi Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute, Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.akashirx.com/</url>
    <description>Sponsor company website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>halofuginone hydrobromide</keyword>
  <keyword>anti-fibrotic</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>muscle regeneration</keyword>
  <keyword>protein synthesis inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Halofuginone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

